Genentech 1Q Revenues: $2.8 billion (+43%) 1Q Income: $706 million (+68%) Comments: U.S. sales rose 30% to $2.0 billion, driven by growth in Avastin sales (+34% to $533 million) and Rituxan (+12% to $535 million). R&D costs increased 63% to $610 million, including $33 million in stock-based compensation for employees....